Alcon stock faces tighter 2026 outlook after mixed Q3

Published on 11/12/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon stock traded at 65.04 euros on Lang & Schwarz on November 12. The company reported stronger core earnings but narrowed its 2026 outlook after mixed third-quarter performance.

Alcon narrows its 2026 outlook

Third-quarter sales rose 5% as Surgical and Vision Care both expanded.
Core earnings increased, but U.S. implantables faced competitive pressure.
The tighter forecast puts execution and new-product adoption at the center of the investment case.

Alcon Inc., CH0432492467, Illustration mit AI erstellt.

Alcon reported stronger core earnings but softer sales momentum in the third quarter ended September 30, 2026, and narrowed its full-year outlook. The results and guidance were reported by AD HOC NEWS.

Alcon stock traded at 65.04 euros on Lang & Schwarz at 17:07 CET on Thursday, November 12, 2026.

That quote was 2.86 percent above the 63.23 euros cited in the latest report at 10:44 CET on Wednesday, November 11. The comparison is separate from a daily exchange benchmark.

Quarterly growth was uneven

Third-quarter sales rose 5 percent to 2.717 billion US dollars. Surgical revenue increased 4 percent to 1.480 billion US dollars, while Vision Care revenue advanced 6 percent to 1.237 billion US dollars.

Implantables sales fell 2 percent to 422 million US dollars as competitive pressure in the United States weighed on intraocular lens demand. Ocular health revenue rose 8 percent to 500 million US dollars, supported by the dry-eye portfolio.

Core earnings continued to improve

Core diluted earnings per share rose 15 percent to 0.91 US dollars, while reported diluted earnings per share increased 13 percent to 0.54 US dollars. Core operating income gained 13 percent to 591 million US dollars, lifting the core operating margin to 21.8 percent from 20.2 percent.

Reported nine-month earnings included a 402 million US dollar pretax, non-cash charge tied to discontinued PowerVision programs. Core diluted earnings per share for the first nine months reached 2.60 US dollars, up 14 percent.

Guidance leaves less room for surprises

Alcon now expects 2026 sales growth of approximately 6 percent in constant currency, compared with its former range of 5 percent to 7 percent. The company also narrowed its expected core operating-margin expansion to 100 to 150 basis points from 90 to 190 basis points.

Core diluted earnings per share growth is now forecast at 12 percent to 14 percent, versus the previous range of 12 percent to 15 percent. Management pointed to newer products, the pipeline and the Neurotech acquisition as longer-term growth drivers.